Video Insights
In a narrative review Dr. Krina Patel participated in and describes in this interview, myeloma experts engaged this question.
Dr. Ryan Jacobs reviews the latest CLL data, highlighting time-limited regimens, BTK combos, and clinical trial updates.
Side effects are an important consideration when using bispecific antibodies in this population, Dr. Krina Patel explains.
The phase 3 SENTRY trial will randomize patients to ruxolitinib plus placebo or selinexor plus placebo.
Dr. Krina Patel was part of a comparative study team which evaluated these two therapies' efficacy and safety in MM care.
Robert Daly, MD discusses how symptom monitoring after discharge can reduce readmissions in cancer care.
Ruchi Desai, MD, specifies what improvements are needed today in the therapy options available for myelofibrosis.
Naval Daver, MD reviews new immunotherapy and targeted strategies transforming ALL treatment and outcomes.
Ruchi Desai, MD, speaks on the challenges of clinical evaluation and therapy optimization in myelofibrosis.
Dr. Sanam Loghavi outlines genetic testing, MRD monitoring, and evolving strategies in newly diagnosed CLL.
Dr. John Mascarenhas discussed novel type 2 JAK inhibitors for myelofibrosis, such as AJ1-11095 and INCB160058.
Our expert roundtable reacts to data presented at ASCO 2025 on real-world use of the agent in this setting.
Experts discuss what data do clinicians need in order to optimize their first-line use of this agent for low-risk MDS.
NKTR-255 plus liso-cel shows promise in boosting CD8+ CAR T cells and improving remission in R/R LBCL.
Our expert panel reacts to the updated efficacy and safety data for luspatercept presented at ASCO 2025.
Panelists discuss how these biomarkers factor into their therapy choices and the impact of new data from ASCO 2025.
New CAR T and bispecific therapies are reshaping myeloma care. Here's what the latest data reveals.
Manali Kamdar, MD, assesses the effect on clinical practice from these label updates for CD19- and BCMA-targeting therapies.
Experts explore inflammation, immune escape, and diverging approaches in managing precursor myeloma.
TAG shows promise for BPDCN patients under 50, reducing toxicity and enabling safer transplants.
Tuspetinib plus standard of care venetoclax and azacitidine in newly-diagnosed AML showed promising safety and efficacy.
Paola Ghione, MD, discusses these findings and how breast implant-associated anaplastic large cell lymphoma is managed.
Pirtobrutinib, CAR T, and bispecifics are reshaping CLL care for high-risk, relapsed patients with limited options.
BTK inhibitor safety: New analysis shows less hypertension risk with acalabrutinib or zanubrutinib vs ibrutinib in CLL.
Josie Ford, of Mass General Hospital, shared real-world efficacy and safety data on duvelisib and romidepsin in PTCL.
Dr. Idoroenyi Amanam explains why luspatercept offers new hope for patients with low-risk myelodysplastic syndromes.
Immunotherapy is reshaping ALL care, and short blinatumomab use may boost outcomes and reduce chemo-related toxicity.
The phase 1/2 study's safety and efficacy data on bexmarilimab plus azacitidine for high-risk MDS are promising.
Dr. O’Brien described the safety and efficacy of zanubrutinib and the benefits of combining the drug with other agents.
Dr. Susan Bal unpacks the promise of GPRC5D CAR T therapy in relapsed/refractory multiple myeloma.
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.